Table 1.
Case-patient clinico-demographic characteristics.
| Total case-patients, n | 244 |
| Age, years; median (IQR) | 42 (29–64.75) |
| Gender, male; n (%) | 128 (52.5) |
| Vaccination status, yes; n (%) | 198 (81.1) |
| Type of vaccine; n (%) | |
| AZD1222 | 141 (57.8) |
| BBV152 | 43 (17.6) |
| BNT162b2 | 10 (4.1) |
| mRNA-1273 | 4 (1.6) |
| Number of vaccine doses administered; n (%) | |
| One dose | 7 (2.9) |
| Two doses | 134 (54.9) |
| Three or more doses | 57 (23.3) |
| History of COVID-19, yes; n (%) | 44 (18) |
| Vaccination prior to COVID-19 disease, yes; n (%) | 199 (81.6) |
| Underlying conditions, yes; n (%) | 81 (33.2) |
| Severity, n (%) | |
| Asymptomatic | 55 (22.6) |
| Mild | 151 (61.9) |
| Moderate | 24 (9.8) |
| Severe | 14 (5.7) |
| Medical support, n (%) | |
| Hospitalisation | 69 (28.3) |
| Oxygen support | 4 (1.6) |
| HDU/ICU admission | 6 (2.5) |
| Ventilator | 0 (0) |
| Clinical outcomes, n (%) | |
| Terminally ill | 6 (2.5) |
| Recovered | 238 (97.5) |
| SARS-CoV-2 variants, n (%) | |
| XBB | 24 (9.8) |
| XBB.1 | 56 (23) |
| XBB.2 | 20 (8.2) |
| XBB.3 | 139 (57) |
| XBB.5 | 5 (2) |
All data reported as numbers (n) and percentages (%) except for age which is reported as median (IQR).
HDU, high dependency unit; ICU, intensive care unit.
BNT162b2 (Pfizer-BioNTech) is a lipid nanoparticle-formulated, nucleoside-modified mRNA vaccine; mRNA-1273 is an mRNA-based vaccine that contains elasomeran, which instructs the host cell to produce a protein from the original strain of SARS-CoV-2; AZD1222 is an adenoviral vector-based vaccine; BBV152 is a whole-virion-based inactivated vaccine.